Non–ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS)
🫀 Non–ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS)
🔹 Definition
NSTE-ACS includes:
- Unstable Angina (UA)
- Non–ST-Elevation Myocardial Infarction (NSTEMI)
Both result from partial or transient occlusion of a coronary artery by a non-occlusive thrombus due to plaque rupture or erosion.
🔹 Pathophysiology
- Atherosclerotic plaque rupture → exposure of subendothelial collagen → platelet activation → thrombus formation
- Incomplete occlusion → ischemia (vs. STEMI where occlusion is complete)
- NSTEMI = myocyte necrosis → ↑ troponin
- UA = ischemia without myocyte necrosis → normal troponin
🔹 ECG Findings
- No persistent ST elevation
- ST-segment depression
- T-wave inversion
- Transient ST elevation (<20 min) may occur
🔹 Biomarkers
| Marker | UA | NSTEMI |
|---|---|---|
| Troponin | Normal | Elevated |
| CK-MB | Normal | Elevated |
🔹 Diagnosis
- Clinical presentation: Chest pain (retrosternal, radiating, >20 min, at rest or minimal exertion)
- ECG changes: ST depression/T inversion
- Cardiac biomarkers: Troponin I/T
Diagnosis confirmed by:
- Ischemic symptoms
- ECG evidence (no persistent ST elevation)
- Biomarker elevation (for NSTEMI)
🔹 Risk Stratification
Use GRACE or TIMI risk scores to guide management.
High-risk features:
- Recurrent angina at rest
- Dynamic ST-T changes
- Elevated troponin
- Hemodynamic instability
- Ventricular arrhythmia
- Diabetes / CKD / prior MI
🔹 Management
🧴 Initial Medical Therapy (MONA-BASH)
| Step | Drugs | Notes |
|---|---|---|
| M | Morphine | Pain relief |
| O | Oxygen | Only if SpO₂ < 90% |
| N | Nitrates | Relieve ischemia |
| A | Aspirin | 325 mg loading + maintenance |
| B | Beta-blocker | Within 24 hr unless contraindicated |
| A | Antiplatelet (P2Y₁₂ inhibitor) | Clopidogrel, Ticagrelor, or Prasugrel |
| S | Statin (high-dose) | Atorvastatin 80 mg |
| H | Heparin (UFH / LMWH / Fondaparinux) | Anticoagulation |
🔹 Revascularization Strategy
- Immediate (<2 hr): Ongoing chest pain, hemodynamic instability, life-threatening arrhythmias
- Early invasive (<24 hr): GRACE >140, dynamic ST-T changes, ↑ troponin
- Conservative: Low-risk (normal biomarkers, no ECG changes)
🔹 Secondary Prevention
- Dual antiplatelet therapy (DAPT): Aspirin + P2Y₁₂ inhibitor (12 months)
- Beta-blockers
- Statins (high-intensity)
- ACE inhibitors/ARBs
- Lifestyle modification
🔹 Key Differences Between NSTEMI & Unstable Angina
| Feature | Unstable Angina | NSTEMI |
|---|---|---|
| Troponin | Normal | Elevated |
| Myocyte necrosis | No | Yes |
| ECG | ST depression/T inversion | Same |
| Management | Similar | Similar |
🫀 Non–ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) — 20 MCQs
📘 Advanced FAQs — Non–ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS)
1️⃣ What distinguishes NSTEMI from unstable angina pathophysiologically?
NSTEMI involves myocyte necrosis caused by transient or partial coronary occlusion, reflected by troponin elevation. Unstable angina, however, shows ischemia without necrosis, with normal troponin levels. Both share similar ECG findings (ST depression, T-wave inversion).
2️⃣ What is the role of high-sensitivity troponin assays in NSTE-ACS diagnosis?
High-sensitivity troponin (hs-cTn) allows earlier detection (within 1–3 hours) and better risk stratification. A rising and/or falling pattern confirms acute myocardial injury. Stable elevated levels suggest chronic disease (e.g., CKD).
3️⃣ How do TIMI and GRACE scores differ in NSTE-ACS risk assessment?
TIMI Score (simpler) includes 7 binary variables predicting 14-day mortality or MI. GRACE Score (more comprehensive) predicts in-hospital and 6-month mortality using continuous variables (age, HR, BP, creatinine, etc.) and is preferred for invasive strategy guidance.
4️⃣ What are the ESC 2023 guidelines for invasive management in NSTE-ACS?
According to ESC 2023 guidelines:
- 🕐 Immediate (<2 h): Hemodynamic instability, refractory angina, life-threatening arrhythmias.
- ⏰ Early (<24 h): GRACE >140, dynamic ST-T changes, elevated troponin.
- 🩶 Delayed/conservative: Stable, low-risk patients (normal troponin, no ECG change).
5️⃣ What are the key pharmacologic differences between NSTEMI and STEMI management?
Thrombolytics are contraindicated in NSTE-ACS as occlusion is incomplete. Otherwise, both share dual antiplatelet therapy, statins, beta-blockers, and anticoagulation. NSTEMI focuses on antithrombotic therapy + early PCI, while STEMI prioritizes immediate reperfusion (PCI/thrombolysis).
6️⃣ What is the role of fondaparinux compared to enoxaparin in NSTE-ACS?
Fondaparinux (Factor Xa inhibitor) is preferred in conservative strategy due to lower bleeding risk compared to LMWH. If PCI is performed, UFH must be added to prevent catheter thrombosis.
7️⃣ Which clinical trials influenced modern NSTE-ACS therapy?
Key trials include:
- CURE: Validated dual antiplatelet therapy (Aspirin + Clopidogrel).
- FRISC II / RITA 3: Supported early invasive strategy.
- PLATO: Demonstrated ticagrelor superiority over clopidogrel.
- ACUITY / OASIS 5: Compared anticoagulation regimens.
8️⃣ What defines refractory angina in NSTE-ACS?
Refractory angina refers to ischemic chest pain persisting despite optimal medical therapy (nitrates, beta-blockers, morphine). It indicates ongoing ischemia and mandates immediate invasive evaluation.
9️⃣ How is NSTE-ACS managed in patients with chronic kidney disease (CKD)?
Use low-dose anticoagulants (fondaparinux preferred), avoid nephrotoxic contrast, and adjust drug doses (e.g., LMWH, ACE inhibitors). Troponin interpretation requires serial testing due to chronic elevation in CKD.
🔟 What secondary prevention measures improve long-term outcomes after NSTE-ACS?
Key measures:
- Continue DAPT for 12 months
- High-intensity statin (Atorvastatin 80 mg)
- Beta-blocker and ACE inhibitor therapy
- Lifestyle changes: smoking cessation, BP & diabetes control, cardiac rehab
📘 Summary: Non–ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS)
Non–ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) includes unstable angina and NSTEMI. It occurs due to partial or transient coronary artery occlusion from a non-occlusive thrombus following plaque rupture. The ECG typically shows ST depression or T-wave inversion, and troponin elevation distinguishes NSTEMI from unstable angina. Risk stratification is done with GRACE or TIMI scores. Management follows the MONA-BASH protocol—Morphine, Oxygen (if SpO₂<90%), Nitrates, Aspirin, Beta-blocker, Antiplatelet, Statin, and Heparin. High-risk patients require early invasive strategy within 24 hours, while low-risk cases can be managed conservatively. Long-term therapy includes DAPT for 12 months, beta-blockers, ACE inhibitors, and high-intensity statins.
NSTE-ACS, NSTEMI, unstable angina, troponin, ST depression, T-wave inversion, partial occlusion, plaque rupture, MONA-BASH, DAPT, GRACE score, TIMI score, high-intensity statin, early invasive strategy, non-ST elevation MI, acute coronary syndrome, NEET-PG, INI-CET, USMLE cardiology, ischemic heart disease, coronary artery disease, antiplatelet therapy, fondaparinux, beta-blocker, statin therapy
NSTE-ACS, NSTEMI, unstable angina, acute coronary syndrome, myocardial ischemia, partial occlusion, troponin elevation, high-sensitivity troponin, TIMI score, GRACE score, PCI, coronary angiography, ESC 2023 guidelines, dual antiplatelet therapy, fondaparinux, clopidogrel, ticagrelor, FRISC II trial, PLATO trial, CURE trial, pathophysiology of NSTE-ACS, risk stratification, early invasive strategy, anticoagulation, secondary prevention
